efficacy of glp 1 receptor agonists Pharmacological interventions for obesity in patients with inflammatory bowel disease: A systematic review GLP-1 agonist and safety Trajectory of weight regain after

In analyses stratified by pre-existing diabetes, we found that the increased risk of preterm birth was only present when GLP-1 RAs were used for diabetes treatment: liraglutide (n = 101, aOR 1.70, 95% CI 1.172.48) and semaglutide (n = 110, aOR 1.84, 95% CI 1.242.71) (Fig

While the study missed its primary endpoint it reported a reduction in heavy alcohol consumption among participants with obesity (Klausen Jensen Mller)

R., Cho, H

Many people start at a low dose and titrate upward to a maintenance level, which can affect side effect patterns

TGR5 and FXR are expressed in enteroendocrine L-cells in the intestine

Greene AK, Zurakowski D, Goss JA